🇯🇵 Japan Country × Condition
hyperphosphatemia patients on hemodialysis Clinical Trials in Japan
Active clinical trials for hyperphosphatemia patients on hemodialysis with research sites in Japan. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 2 // Recruiting: 2 Phases: Phase 3 // Updated: Daily
Total Trials
2
Recruiting Now
2
Country
🇯🇵 Japan
Active Trials in Japan (2)
NCT07285291 Phase 3
Recruiting
A Phase 3 Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis With Phosphate Binders
Enrollment
100 pts
Country
🇯🇵 Japan
Taisho Pharmaceutical Co., Ltd.
View Trial → NCT07285304 Phase 3
Recruiting
A Long-term Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Enrollment
300 pts
Country
🇯🇵 Japan
Taisho Pharmaceutical Co., Ltd.
View Trial → Frequently Asked Questions
How many hyperphosphatemia patients on hemodialysis clinical trials are active in Japan?
There are currently 2 active clinical trials for hyperphosphatemia patients on hemodialysis with sites in Japan, of which 2 are actively recruiting patients.
How can I join a hyperphosphatemia patients on hemodialysis clinical trial in Japan?
To join a hyperphosphatemia patients on hemodialysis clinical trial in Japan, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Japan directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are hyperphosphatemia patients on hemodialysis trials in Japan?
Active hyperphosphatemia patients on hemodialysis trials in Japan span Phase 3. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology